vax exam2

Birth

Recombivax/Energix-B

Nirsevimab (if applicable)

2 months

Recombivax/Energix-B

Infanrix/Daptacel

RotaTeq/Rotarix

ActHIB/Hiberix/PedvaxHIB

IPOL

Prevnar 20/Vaxneuvance

4 months

Infanrix/Daptacel

RotaTeq/Rotarix

ActHIB/Hiberix/PedvaxHIB

IPOL

Prevnar 20/Vaxneuvance

6 months

Recombivax/Energix-B

Infanrix/Daptacel

RotaTeq/Rotarix

ActHIB/Hiberix

IPOL

Prevnar 20/Vaxneuvance

(Afluria/Flurix/Fluzone/Flucelvax/Flulaval) x2

12 months

Priorix/MMRII

Havrix/Vaqta

Daptacel/Infanrix

ActHIB/Hiberix/PedvaxHIB

Prevnar 20/Vaxneuvance

Varivax

15 months

Daptacel/Infanrix

4 years

Varivax

Daptacel/Infanrix

IPOL

Priorix/MMRII

11-12 years

Boostrix/Adacel

Gardasil-9

Menveo/MenQuadfi

16 years

Menveo/MenQuadfi

50 years

Shingrix

Prevnar 20/Vaxneuvance+Pneumovax/Capvaxive

65 years

Comirnaty/Spikevax/Mnexspike/Nuvaxovid

75 years

Arexvy/Abrysvo

Flu

19-64 for immunosuppressed

Fluad/Fluzone-HD

Pneomococcal

24-59 months for incomplete PCV series

Vaxneuvance/Prevnar-20

2-18 years with certain medical conditions (completely vaccinated)

Prevnar20/Pneumovax 8 weeks after last PCV

6-18 years with certain medical conditions (no PCV)

Prevnar20/Vaxneuvance + Pneumovax 8 weeks later

19-64 with certain medical conditions

Prevnar20/Vaxneuvance + Pneumovax 1 year later

RSV

50-74 at increased risk

Abrysvo/Arexvy

Meningococcal

Adults with certain medical conditions

Menveo/MenQuadfi 2 doses 8 weeks apart

Adults at continued risk

Revaccinate every 5 years

Meningococcal B

Outbreaks of Meningococcal B/Healthy individuals 16-23/10+ years at risk

Trumenba/Bexsero

Tdap

Administer Boostrix/Adacel when applicable to all family members/caregivers of infant

Varicella

Age 7-12 years no immunity: 2 doses Varivax 3 months apart

Age >13 no immunity: 2 doses Varivax 4-8 weeks apart

HPV

Immunocompromised patients regardless of age

Gardasil-9 3-dose series

DONT GIVE TO YEAST ALLERGIC PATIENTS

Shingles

19+ immunocompromised

Shingrix

MMR

Students/healthcare with no evidence of immunity

2 doses MMRII/Priorix 4 weeks apart

Heptatitis A

Adults with risk factors/anyone who wants immunity

Havrix/Vaqta/Twinrix (adults)

Menveo

ACWY

2-55 years old

MenQuadfi

ACWY

2 years or older

Recommendations for Meningococcal Vaccine

1 dose of MVC4 11-12 years old

1 booster of MCV4 at 16 years old if first dose administered before 16th birthday

Only 1 dose needed if first dose is after 16 years old

Not routinely recommended 19+

Trumenba

Meningococcal B

1 dose at 0 months, 1 dose at 6 months

Bexsero

Meningococcal B

1 dose at 0 months, 1 dose at 1-6 months

Risk and Recommendations for MenB vaccine

Outbreaks of MenB

College campuses

16-23 years old may receive a series to provide short-termed protection

10+ years or older at risk may receive booster 1 year after primary series followed by booster every 2-3 years the risk remains

PENBRAYA

ABCWY

2-dose, 6 months apart

Trumenba + Nimenrix

Penmenvy

ABCYW

Bexsero + Menveo

2-dose, 6 months apart

Daptacel

DTaP

6 weeks to 6 years

Infanrix

DTaP

6 weeks to 6 years

Adacel

Tdap

10 years to 64 years

Boostrix

Tdap

10 years or greaterR

Tenivac

TD

7 years or older

1 dose every 10 years

TdVax

TD

7 years or older

1 dose every 10 years

Recommendations for Tdap Vaccines

One dose every pregnancy preferably 27-36 weeks or ASAP post-partum

All family members should receive too

Use DTaP for 6 weeks to 6 year olds (2, 4, 6 months, 4 years)

For age 11 and older, give a single Tdap dose and a booster of Td or Tdap every 10 years

For 65 years or older, use Boostrix (or Adacel if Boostrix not available)

PPSV

Polysaccharide (from different serotype/subgroup/variation)

T-cell independent immune response

PCV

Polysaccharides attached/conjugated to carrier protein

T-cell dependent response that produces memory B-cells

VAXNEUVANCE

PCV15

6 weeks or older

Prevnar 20

PCV20

6 weeks or older

Capvaxive

PCV21

18 years or older

2-17 years old risk group (must have completed PCV series)

Pneumovax

PPSV23

50 years and older

2 years or older for pneumococcal risk group

Recommendations for Infant Vaccination

PCV15 or PCV20

Doses at 2, 4, 6, 12-15 months

2-18 years with certain medical conditions and completely vaccinated before 6 years can receive PCV20 or PPSV23 8 weeks after last PCV (except when PCV20 was given)

6-18 years with certain medical conditions w/o PCV dose receive PCV20 or PCV15+PPSV23 at least 8 weeks after

Recommendations for Adult Vaccine

50 years or older receives either PCV20/PCV21 or PCV15+PPSV23 8 weeks-1 year later

19-64 years with certain medical conditions have same recommendation

Medical Conditions and Factors for Adult Pneumococcal Vaccines

Alcoholism

Chronic heart, liver, or lung disease

Chronic renal failure

Smoking

Congenital/acquired asplenia

CSF leak

Diabetes

Generalized Malignancy

HIV

Immunosuppression

Leukemia/Lymphoma/Multiple myeloma

Organ transplant

Sickle Cell

Nirsevimab

Monoclonal antibodies

For babies only

Abrysvo

18 years or older

32-36 weeks of pregnancy within September-January

Once reconstituted, must be used within 4 hours

Arexvy

50 years or older

Once reconstituted, must be used within 4 hours

mRESVIA

60 years or older

18-59 who are at increased risk for LRTD (caused by RSV)

Discard if thawed and in the fridge for up to 24 hours

Do not shake

Recommendations for Adults

All adults 75 or older should receive protein subunit vaccine

Adults 50-74 at increased risk have the same recommendation

Risk Factors for RSV

Chronic cardiovascular, lung, respiratory, liver disease

Diabetes

Severe obesity

End stage renal disease/dialysis dependence

Chronic hematological conditions

Neurological/neuromuscular conditions

Nursing home residence

Moderate+ immunocompromised

IIV3

Standard-dose, unadjuvanated inactivated

Egg-based

ccIIV3

Cell culture-based inactivated

Grown in mammalian cells (like MDCK)

aIIV3

Adjuvanted inactivated

Egg-based

Surface proteins blended with oil-in-water adjuvant (MF59)

HD-IIV3

High-dose inactivated

Egg-based

4x antigen

RIV3

Recombinant

Gene that contains instructions for making HA then combined with baculovirus

LAIV3

Live attenuated

Egg-based

Temperature-sensitive

Afluria

IIV3

6 months and older

Fluarix

IIV3

6 months and older

FluLaval

IIV3

6 months and older

Fluzone

IIV3

6 months and older

Flucelvax

ccIIV3

6 months and older

Flublok

RIV3

9 years and older

Fluzone HD

IIV3-HD

65 years and older

Fluad

aIIV3

65 years and older

FluMist

LAIV3

2-49 years old

mFlusiva

mRNA

50 years or older

Do not shake

Recommendations for Influenza Vaccine

Most people: 1 dose beginning September/October

Children between 6 months to 8 years must receive 2 doses administered 4 weeks or more apart if it is their first time ever

Pregnant people (inactivated)